CN Patent

CN110330484B — 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途

Assigned to China Pharmaceutical University · Expires 2022-08-26 · 4y expired

What this patent protects

本发明公开了具有通式(I)的取代类苯基嘧啶衍生物作为JAK激酶抑制剂或其可药用的盐、制备方法及用途。该化合物具有优良的JAK抑制作用，其用作预防、治疗或改善自身免疫疾病、斯耶格伦氏综合征、白塞氏病、多发性硬化、系统性红斑狼疮等的药物。本发明化合物表现出高活性的JAK‑3抑制作用IC 50 可达到1.7nM，本发明合成路线简单，实施性强。

USPTO Abstract

本发明公开了具有通式(I)的取代类苯基嘧啶衍生物作为JAK激酶抑制剂或其可药用的盐、制备方法及用途。该化合物具有优良的JAK抑制作用，其用作预防、治疗或改善自身免疫疾病、斯耶格伦氏综合征、白塞氏病、多发性硬化、系统性红斑狼疮等的药物。本发明化合物表现出高活性的JAK‑3抑制作用IC 50 可达到1.7nM，本发明合成路线简单，实施性强。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN110330484B
Jurisdiction: CN
Classification: —
Expires: 2022-08-26
Drug substance claim: No
Drug product claim: No
Assignee: China Pharmaceutical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.